← Issue №13/ week of Sep 27, 2026/Hepatology

Prevalence of liver fibrosis and steatotic liver disease in community-dwelling adults in China (the CHESS-LiverHealth project): cross-sectional baseline data from a prospective cohort study.

From GI Signals issue №13: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology prospective cohort · n=18,000 · Sep 22, 2026 · Lancet GH · IF 39.1

Prevalence of liver fibrosis and steatotic liver disease in community-dwelling adults in China (the CHESS-LiverHealth project): cross-sectional baseline data from a prospective cohort study.

EpidemiologyepidemiologyMASLDalcohol-associated liver diseasebiomarker
Clinical takeawayNo clinical action yet: epidemiological data establishing baseline prevalence in China. Consider heightened awareness for liver fibrosis and steatotic liver disease in high-risk groups (obesity, diabetes, alcohol use).
What it foundPrevalence of liver fibrosis (LSM ≥8 kPa) was 4.4%, and steatotic liver disease (CAP ≥248 dB/m) was 43.7% in community-dwelling Chinese adults, with MASLD accounting for 39.5% of cases.
ContextThis literature reports a high prevalence of liver fibrosis and steatotic liver disease in community-dwelling adults in China, associated with overweight, obesity, diabetes, and harmful alcohol consumption.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Liu S … Qi X · Lancet Gastroenterology & Hepatology · IF 39.1 · PubMed ↗Permalink
← Read the whole of issue №13 Every paper GI Signals surfaces gets a page like this one. All issues